COREE’s HKEX IPO Application Lapsed, China’s Largest Paediatric Pharmaceutical Marketing & Promotion Service Provider
NewTimeSpace News: The Main Board listing application filed by COREE Company Limited with the Hong Kong Stock Exchange on 18 December 2025 has now lapsed after the six-month statutory validity window expired, with CICC serving as the original sole sponsor.
Originating from South Korea, the Company is an integrated healthcare solution vendor whose primary business operations are based in China, while it continues to expand its international business layout. Committed to upgrading pharmaceutical supply chains via digital solutions, it fosters innovative development in biological healthcare and multi-functional nutrition sectors. During the track record period, the Group’s core businesses cover pharmaceutical marketing, promotion and sales, as well as the R&D, production and distribution of maternal, infant and nutritional supplements.
Per Frost & Sullivan industry data based on 2024 revenue, the Company ranks among the top ten players in China’s pharmaceutical marketing, promotion and sales market, and holds the leading position as China’s largest service provider specialised in paediatric pharmaceutical marketing, promotion and sales, with around 15.9% market share nationwide.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- COREE Company Limited Resubmits HKEX Listing Application, China’s Largest Paediatric Pharmaceutical Marketing & Promotion Service Provider
- COREE Company Limited Receives Supplementary Materials Request for Overseas Listing Filing, Focusing on Pledge Risks of All Shares and Full Compliance of Round-Trip M&A
- MIN FU INTL(08511.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at loss of HKD 8.35 million, loss narrowed by 69.45% YoY
- SUNMI TECH-W (06810.HK): Cornerstone Investor XINWUTANG CO., LIMITED Voluntarily Extends Lock-Up Period by Five Months to March 28, 2027
- CA CULTURAL (01566.HK): Independent Investigation Completed with No Evidence of Fraud or Misappropriation, Reports Adopted, Trading Remains Suspended
